Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc.

CourtDistrict Court, S.D. New York
DecidedFebruary 19, 2020
Docket1:19-cv-03351
StatusUnknown

This text of Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc. (Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc., (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT U DS OD CC U MSD EN NY T SOUTHERN DISTRICT OF NEW YORK ELECTRONICALLY FILED ------------------------------------------------------------------- X DOC #: : DATE FILED: 02/19/2 020 AQUAVIT PHARMCEUTICALS, INC., : : Plaintiff, : : 19-CV-3351 (VEC) -against- : : OPINION AND ORDER U-BIO MED, INC., GLOBAL MEDI PRODUCTS, : and NYUN SHI EUM aka NYON-SIK EUM, : : Defendants. : : ------------------------------------------------------------------- X VALERIE CAPRONI, United States District Judge: In this trademark infringement action, Defendants U-Bio Med, Inc. and Nyun Shi Eum1 (“Defendants”) moved to dismiss the Complaint for lack of personal jurisdiction, claiming that a licensing agreement, which contains a forum selection clause and a consent to personal jurisdiction in New York, is unenforceable, and that Defendants’ alleged infringing activity does not subject them to jurisdiction by way of New York’s long-arm statute. Because the Court finds that the agreement is enforceable, the motion to dismiss is denied. I. BACKGROUND On July 14, 2013, the parties entered into a licensing agreement that allowed Plaintiff, the licensee, to market and reproduce Defendants’ injection device, which was allegedly patented and had medical or cosmetic applications. See Exclusive Worldwide Licensing Agreement (“EWLA”) (Dkt. 1-1) at 1; Compl. (Dkt. 1) ¶ 2. Per the EWLA, Plaintiff must pay Defendants an annual royalty fee based on the number of devices sold, as set forth in a fee schedule. EWLA 1 Defendant Global Medi Products has not appeared in this action or otherwise responded to the Complaint. (Dkt. 1-1) at 2.2 Plaintiff has the option of fulfilling any sales orders by purchasing the devices from Defendants, at a price that guarantees Defendants a margin of 40%, or manufacturing the devices itself. EWLA (Dkt. 1-1) at 3. The EWLA also contains numerous other provisions, including non-compete and non-solicitation clauses binding on all parties until 24 months after the termination of the agreement. EWLA (Dkt. 1-1) at 4.

Starting in March 2014, Plaintiff began marketing the injection devices under the trade name AQUAGOLD. Compl. (Dkt. 1) ¶ 103. According to the Complaint, Plaintiff purchased the injection devices from Defendants until sometime in December 2014 or early 2015; Defendants’ shipments were incomplete, unsanitary, or defective. Id. ¶¶ 111–12. By late 2014, Plaintiff allegedly learned that Defendants’ manufacturing facilities were not certified, and that Defendants did not own the intellectual property behind the devices. Id. ¶¶ 110, 114. Plaintiff then found another manufacturing partner to produce the AQUAGOLD devices in certified facilities. Id. ¶ 115. Up to that point, Plaintiff had paid Defendants more than $200,000.3 Id. at ¶ 112.

Since then, the relationship between the parties has significantly deteriorated. Defendants have allegedly attempted to convince actual and prospective customers that their device, marketed as Tappy Tok-Tok, is the functional equivalent of Plaintiff’s AQUAGOLD device. Id. ¶¶ 121–24. In April 2016, Defendants sent a letter to three of Plaintiff’s customers in New York City, claiming that Plaintiff had stolen the injection device’s technology from

2 The fee schedule provides for a royalty of 25% of the wholesale price for the first 10,000 to 50,000 units. EWLA (Dkt. 1-1) at 2. The annual royalty for sales of less than 10,000 units is unclear.

3 It is not clear from the Complaint whether the $200,000 represents royalty payments, guaranteed margin, or some combination of the two. Defendants. See id. ¶ 121; Dkt. 1-8 at 2. Defendants also allegedly began selling injection devices that bore Plaintiff’s AQUAGOLD trademarks. Compl. (Dkt. 1) ¶ 124. Defendants’ online advertising, on their website and social media pages, describe Plaintiff’s product as “fake.” Id. ¶ 143. Defendants have allegedly used Facebook to send disparaging messages about Plaintiff to Plaintiff’s distributors. Id. ¶¶ 147–48. On Instagram,

Defendants have used the handle @tappy_aquagold to post numerous images of AQUAGOLD. Id. ¶ 146. Additionally, on March 19, 2019, a “Warning Notice” was posted on the U-Biomed website, claiming that Plaintiff stole Defendants’ intellectual property. Id. ¶ 186. Plaintiff alleges that multiple distributors have been confused by Defendants’ marketing strategies and have demanded that Plaintiff lower the price of AQUAGOLD, which sold for $175 each, to compete with Defendants’ advertised price of $20. Id. ¶¶ 177–84. Plaintiff has also reportedly received complaints from confused customers who received marketing communications from Defendants. Id. ¶ 185. On April 15, 2019, Plaintiff commenced this action, alleging breach of contract (the

EWLA), trademark infringement and false advertising pursuant to the Lanham Act, tortious interference, defamation, unfair competition, and deceptive business practices. See generally Compl. (Dkt. 1). On the same day, Plaintiff sought a temporary restraining order, which was granted and later converted into a preliminary injunction when Defendants failed to appear at the hearing. Dkts. 3,19. Defendants later filed a motion to modify the preliminary injunction, which was granted, Dkt. 65, and a motion to dismiss this case for lack of personal jurisdiction, which is now before the Court. II. DISCUSSION On a Rule 12(b)(2) motion to dismiss, the plaintiff has the burden of demonstrating personal jurisdiction. Troma Entm’t, Inc. v. Centennial Pictures Inc., 729 F.3d 215, 217 (2d Cir. 2013) (citing Penguin Grp. (USA) Inc. v. Am. Buddha, 609 F.3d 30, 34 (2d Cir. 2010)). “[W]hen the issue of personal jurisdiction ‘is decided initially on the pleadings and without discovery, the

plaintiff need show only a prima facie case.’” King Cty., Wash. v. IKB Deutsche Industriebank, AG, 769 F. Supp. 2d 309, 313 (S.D.N.Y. 2011) (citing Volkswagenwerk Aktiengesellschaft v. Beech Aircraft Corp., 751 F.2d 117, 120 (2d Cir. 1984)). To overcome Defendants’ challenge to the sufficiency of the Complaint, Plaintiff need only have “plead[ed] facts which, if true, are sufficient in themselves to establish jurisdiction.” See Tamam v. Fransabank Sal, 677 F. Supp. 2d 720, 725 (S.D.N.Y. 2010) (citing Bellepointe, Inc. v. Kohl’s Dep’t Stores, Inc., 975 F. Supp. 562, 564–65 (S.D.N.Y. 1997)). For purposes of this motion, the Court must assume the truth of Plaintiff’s well-pleaded factual allegations. See Ball v. Metallurgie Hoboken-Overpelt, S.A., 902 F.2d 194, 197 (2d Cir. 1990); Tamam, 677 F. Supp. 2d at 725.

Plaintiff cites three alternative bases for personal jurisdiction—the EWLA, which contains an agreement to submit to the jurisdiction of federal and state courts in New York for the adjudication of any disputes arising from the agreement, and two provisions of the New York long-arm statute, which pertain to the transaction of business in New York and the commission of tortious acts causing harm in New York. Compl. (Dkt. 1) ¶ 21. A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Penguin Group (USA) Inc. v. American Buddha
609 F.3d 30 (Second Circuit, 2010)
Robert L. Haag, Inc. v. Swift & Company
696 F.2d 30 (Second Circuit, 1982)
Bruce Ball v. Metallurgie Hoboken-Overpelt, S.A.
902 F.2d 194 (Second Circuit, 1990)
Bellepointe, Inc. v. Kohl's Department Stores, Inc.
975 F. Supp. 562 (S.D. New York, 1997)
Tamam v. Fransabank Sal
677 F. Supp. 2d 720 (S.D. New York, 2010)
Dalton v. Educational Testing Service
663 N.E.2d 289 (New York Court of Appeals, 1995)
King County, Wash. v. Ikb Deutsche Industriebank
769 F. Supp. 2d 309 (S.D. New York, 2011)
Chicago & Great Eastern Railway Co. v. Dane
43 N.Y. 240 (New York Court of Appeals, 1870)
Willetts v. . the Sun Mutual Ins. Co.
45 N.Y. 45 (New York Court of Appeals, 1871)
Oscar Schlegel Manufacturing Co. v. Peter Cooper's Glue Factory
132 N.E. 148 (New York Court of Appeals, 1921)
Grossman v. . Schenker
100 N.E. 39 (New York Court of Appeals, 1912)
Mar-Bond Beverage Corp. v. Dublin Distributors, Inc.
9 A.D.2d 951 (Appellate Division of the Supreme Court of New York, 1959)
Baum v. Beacon Feeds, Beacon Division of Textron, Inc.
31 A.D.2d 734 (Appellate Division of the Supreme Court of New York, 1968)
Kowalchuk v. Stroup
61 A.D.3d 118 (Appellate Division of the Supreme Court of New York, 2009)
Ferguson v. Ferguson
97 A.D.2d 891 (Appellate Division of the Supreme Court of New York, 1983)

Cite This Page — Counsel Stack

Bluebook (online)
Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/aquavit-pharmaceuticals-inc-v-u-bio-med-inc-nysd-2020.